chronic myelogenous leukemia (cml) therapeutics

1. Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

2. The CML Therapeutics Market is forecast to Show Steady Growth Until 2017 GlobalData estimates that the global Chronic Myelogenous Leukemia (CML) therapeutics market was valued at $1,089m in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 24% to reach $3,246m in 2010. The market is forecast to grow at a CAGR of 11% over the next seven years to reach $6,675m by 2017. This decline in growth rate is primarily attributed to the patent expiry of Gleevec in 2015 which would be offset by the expected launch of two promising pipeline molecules, Omapro (omacetaxine mepesuccinate) and bosutinib in 2014. The market remains well-served with the current market products, most of which are significantly efficacious in their respective target areas. Entry of first-in-class molecules in the market will be the primary driver for market growth. Essentially, the global CML market is heading towards a phase of continuous growth, leveraging the current opportunities. Strong Pipeline is Likely to Result in Steady Growth for the CML Market GlobalData’s research indicates that the CML pipeline is strong, with 18 molecules in various phases of clinical development with 13 first-in-class (FIC) molecules. Filed and Phase III have FIC molecules such as Omapro (omacetaxine mepesuccinate) and bosutinib which possess new mechanisms of action to treat CML. To date, both the pipeline products have shown promising clinical study results which would warrant their use in CML. Omapro is in the filed stage, and acts as a Cyclin-D1, Mcl-1 and c-Myc proteins synthesis inhibitor and is effective for imatinib-resistant patients with the T315I mutation. Bosutinib, a Phase III

3. molecule, is a dual Src and ABL inhibitor with activity against most mutants of Bcr-Abl (Breakpoint cluster region/Abelson translocation) and decreased toxicity. Both these products will be responsible for the growth of the CML therapeutics market post-2014. Although the market is adequately served by the current treatment options, the CML therapeutics pipeline will uncover opportunities for new entrants. Changing Future Landscape of CML ChemGenex Pharmaceuticals, Pfizer Inc., Ariad Pharmaceuticals, Synta Pharmaceuticals Corp. and Piramal Life Sciences Limited are expected to be the key players in the CML therapeutics market. The existing market landscape remains competitive, because the treatment of CML relies on established therapies like Gleevec, Sprycel and Tasigna. The market scenario will change after the launch of newer disease-modifying therapies such as Cyclin-D1, Mcl-1 and c-Myc protein synthesis inhibitors, Abl and srcfamily kinase inhibitors, DNA synthesis inhibitors, Hsp90 inhibitors, dual Bcr-Abl and Lyn-kinase inhibitors, Bcr-Abl inhibitors and RAS inhibitors, Bcr-Abl kinase inhibitors, tyrosine kinase inhibitors, Bcr-Abl/JAK2 inhibitors and heat shock protein 32 (Hsp32) inhibitors with enhanced permeability and retention effect (EPR). For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Chronic-Myelocytic-Leukemia-CML-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

4. Moderate Unmet Need Likely to be satisfied by Strong Pipeline Products The CML therapeutics market is represented by three effective products and is dominated by big pharma. Gleevec (imatinib) from Novartis is prescribed as the standard therapy for CML patients. Sprycel (dasatinib) from Bristol-Myers Squibb and Tasigna (nilotinib) from Novartis were approved in June 2006 and October 2007 respectively and are used for Gleevec-resistant CML patients. Recently, Sprycel and Tasigna have also been approved as a first-line treatment for patients with CML by the US Food and Drug Administration (FDA) These three agents adequately cater to the needs of the specific patient group. However, the moderate unmet need arises when Gleevec and other tyrosine kinase inhibitors (TKIs) which are not able to treat patients with mutations such as T315I mutation or who have failed prior TKI therapy. Such patients do not have further treatment options. Thus, there is a need for novel products which can fill the voids created by these current market products. The pipeline products are expected to provide better benefits, with innovative mechanisms of action in comparison to the existing players. GlobalData, the industry analysis specialist, has released its new report, “Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global CML therapeutics market. The report identifies the key trends shaping and driving the global CML therapeutics market. The report also provides insights

5. on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Chronic-Myelocytic-Leukemia-CML-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782